Champions Oncology Inc. (CSBR)
NASDAQ: CSBRHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CSBR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $69.31M
- Forward P/E
- 49.80
- EPS (TTM)
- -$0.07
- Dividend yield
- None
- 52-week range
- 4.59 – 8.31
- Day range
- 4.88 – 5.00
- Volume / Avg
- 2.82K / 11.33K
- Beta
- —
- Shares outstanding
- 13.92M
52-week range
CSBR stock today
Shares of Champions Oncology (CSBR) finished higher on Oct 8 at $4.98, a gain of 2.05% or $0.10 per share, versus the S&P 500's 0.47% decline. Trading was light, with 2.82K shares changing hands, about 25% of the average daily volume. At this level, CSBR sits near the bottom of its 52-week range of $4.59 to $8.31: 40.1% below the high, set on Dec 15, 2025 and 8.5% above the low.
CSBR is down 27.9% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 23.0%. Champions Oncology has posted a net loss over the last twelve months (EPS of -$0.07), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Champions Oncology
Company profileChampions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Robert Brainin
- Headquarters
- Hackensack, NJ
- Employees
- 214
- Website
- championsoncology.com
Champions Oncology peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TENXTenax Therapeutics Inc. | 1.86 | -2.62% | $69.61M | vs CSBR |
| FBIOFortress Biotech Inc. | 2.09 | +2.45% | $69.70M | vs CSBR |
| GANXGain Therapeutics Inc. | 1.62 | -3.29% | $70.48M | vs CSBR |
| HRTXHeron Therapeutics Inc. | 0.3582 | -6.79% | $68.01M | vs CSBR |
| CINGCingulate Inc. | 4.88 | +0.21% | $70.96M | vs CSBR |
| MAIAMAIA Biotechnology Inc. | 1.15 | -2.54% | $71.00M | vs CSBR |
| HYFTMindWalk Holdings Corp. | 1.43 | -4.67% | $67.37M | vs CSBR |
| ONCYOncolytics Biotech Inc. | 0.5444 | -8.63% | $71.38M | vs CSBR |
Indexes, lists and sector
Appears in lists
Champions Oncology stock FAQ
What is Champions Oncology's stock price today?
CSBR last traded at $4.98 as of Oct 8, 4:00 PM EDT, up 2.05% on the day. Prices are delayed at least 15 minutes.
Does Champions Oncology pay a dividend?
No. Champions Oncology does not currently pay a regular cash dividend.
Who is Champions Oncology's CEO?
Mr. Robert Brainin is the chief executive officer of Champions Oncology Inc., which has about 214 employees.
Has CSBR ever split its stock?
Yes. The most recent CSBR stock split was a 1-for-12 split on Aug 12, 2015.
What is the CSBR 52-week high?
The 52-week high for CSBR is $8.31 and the 52-week low is $4.59. The stock is currently 40.1% below its high.